

19 February 2026

ASX Announcement

## Release of Securities from Voluntary Escrow

---

**Firebrick Pharma Limited** (ASX:FRE) (**Firebrick, Company**) advises in accordance with ASX Listing Rule 3.10A that the following securities will be released from voluntary escrow on or after their escrow expiry date.

Securities	Number	Escrow Expiry Date
Ordinary Fully Paid Shares	11,578,947	4 March 2026

The above securities are held by Pharma Nutria NA Inc (**PNAI**), a substantial holder in Firebrick Pharma, an entity that is part of the SV More Group of Companies, which includes the Company's Philippines licensing partner, SV More Pharma Corporation.

Paul Santillana, Director of PNAI and Vice-President of SV More Pharma Corporation, the company's commercial licensee in the Philippines, stated: *"We are excited about our partnership with Firebrick Pharma and we are eagerly awaiting the formal review of the dossier lodged with the Philippines Food and Drug Administration for Nasodine Nasal Spray. As such, we have no intention of selling any of the shares we hold in Firebrick and look forward to supporting Peter and the Firebrick team as they continue to build a significant business."*

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore and Fiji. For further information, visit <https://nasodine-sg.com/>

### Contacts:

**Media contact:**

Matthew Wright, NWR Communications  
matt@nwrcommunications.com.au

**Shareholder Company contact:**

Kam Watson, Firebrick Pharma  
investors@firebrickpharma.com